BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 16533722)

  • 21. Increased plasma EPO and MIP-1 alpha are associated with recruitment of vascular progenitors but not CD34(+) cells in autologous peripheral blood stem cell grafts.
    Labonté L; Li Y; Yang L; Gillingham A; Halpenny M; Giulivi A; Sills T; Evans K; Zanke B; Allan DS
    Exp Hematol; 2009 Jun; 37(6):673-8. PubMed ID: 19463769
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Intravenous busulfan and melphalan, tacrolimus, and short-course methotrexate followed by unmodified HLA-matched related or unrelated hematopoietic stem cell transplantation for the treatment of advanced hematologic malignancies.
    Small TN; Young JW; Castro-Malaspina H; Prockop S; Wilton A; Heller G; Boulad F; Chiu M; Hsu K; Jakubowski A; Kernan NA; Perales MA; O'Reilly RJ; Papadopoulos EB
    Biol Blood Marrow Transplant; 2007 Feb; 13(2):235-44. PubMed ID: 17241929
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Optimizing the timing of chemotherapy for mobilizing autologous blood hematopoietic progenitor cells.
    Hicks ML; Lonial S; Langston A; Flowers C; Roback JD; Smith KJ; Mossavi Sai S; Teagarden D; Hamilton ES; Waller EK; Kaufman J
    Transfusion; 2007 Apr; 47(4):629-35. PubMed ID: 17381621
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Difficult stem cell mobilization despite adequate CD34+ cell dose predicts shortened progression free and overall survival after autologous HSCT for lymphoma.
    Tomblyn M; Burns LJ; Blazar B; Wagner J; Lee C; Rogers T; McGlave P; Miller JS; Weisdorf DJ
    Bone Marrow Transplant; 2007 Jul; 40(2):111-8. PubMed ID: 17530003
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Peripheral blood progenitor cell mobilization with intermediate-dose cyclophosphamide, sequential granulocyte-macrophage-colony-stimulating factor and granulocyte-colony-stimulating factor, and scheduled commencement of leukapheresis in 225 patients undergoing autologous transplantation.
    Bashey A; Donohue M; Liu L; Medina B; Corringham S; Ihasz A; Carrier E; Castro JE; Holman PR; Xu R; Law P; Ball ED; Lane TA
    Transfusion; 2007 Nov; 47(11):2153-60. PubMed ID: 17958545
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Autologous infusion of expanded mobilized adult bone marrow-derived CD34+ cells into patients with alcoholic liver cirrhosis.
    Pai M; Zacharoulis D; Milicevic MN; Helmy S; Jiao LR; Levicar N; Tait P; Scott M; Marley SB; Jestice K; Glibetic M; Bansi D; Khan SA; Kyriakou D; Rountas C; Thillainayagam A; Nicholls JP; Jensen S; Apperley JF; Gordon MY; Habib NA
    Am J Gastroenterol; 2008 Aug; 103(8):1952-8. PubMed ID: 18637092
    [TBL] [Abstract][Full Text] [Related]  

  • 27. EPO in combination with G-CSF improves mobilization effectiveness after chemotherapy with ifosfamide, epirubicin and etoposide and reduces costs during mobilization and transplantation of autologous hematopoietic progenitor cells.
    Hart C; Grassinger J; Andreesen R; Hennemann B
    Bone Marrow Transplant; 2009 Feb; 43(3):197-206. PubMed ID: 18806833
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Factors affecting hematopoietic progenitor cell mobilization: an analysis of 307 patients.
    Mendrone A; Arrais CA; Saboya R; Chamone Dde A; Dulley FL
    Transfus Apher Sci; 2008 Dec; 39(3):187-92. PubMed ID: 19036640
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The evolution of hematopoietic SCT in myelodysplastic syndrome.
    Kindwall-Keller T; Isola LM
    Bone Marrow Transplant; 2009 Apr; 43(8):597-609. PubMed ID: 19252532
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The use of experimental murine models to assess novel agents of hematopoietic stem and progenitor cell mobilization.
    Herbert KE; Lévesque JP; Haylock DN; Prince HM
    Biol Blood Marrow Transplant; 2008 Jun; 14(6):603-21. PubMed ID: 18489986
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Mobilization strategies for the collection of peripheral blood progenitor cells: Results from a pilot study of delayed addition G-CSF following chemotherapy and review of the literature.
    Jacoub JF; Suryadevara U; Pereyra V; Colón D; Fontelonga A; Mackintosh FR; Hall SW; Ascensão JL
    Exp Hematol; 2006 Nov; 34(11):1443-50. PubMed ID: 17046563
    [TBL] [Abstract][Full Text] [Related]  

  • 32. GATA-1 transcription factor is up-regulated in bone marrow hematopoietic progenitor CD34(+) and erythroid CD71(+) cells in myelodysplastic syndromes.
    Maratheftis CI; Bolaraki PE; Voulgarelis M
    Am J Hematol; 2007 Oct; 82(10):887-92. PubMed ID: 17570514
    [TBL] [Abstract][Full Text] [Related]  

  • 33. An antecedent diagnosis of refractory anemia with excess blasts has no influence on mobilization of peripheral blood stem cells and hematopoietic recovery after autologous stem cell transplantation in acute myeloid leukemia.
    Viola A; Falco C; D'Elia R; D'Amico MR; Vicari L; Tambaro FP; Correale P; Laudati D; Palmieri S; Ferrara F
    Eur J Haematol; 2007 Jan; 78(1):41-7. PubMed ID: 17042770
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Perioperative iloprost and endothelial progenitor cells in uremic patients with severe limb ischemia undergoing peripheral revascularization.
    Coppolino G; Buemi A; Bolignano D; Lacquaniti A; La Spada M; Stilo F; De Caridi G; Benedetto F; Loddo S; Buemi M; Spinelli F
    J Surg Res; 2009 Nov; 157(1):e129-35. PubMed ID: 19589539
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Single-dose pegfilgrastim is comparable to daily filgrastim in mobilizing peripheral blood stem cells: a case-matched study in patients with lymphoproliferative malignancies.
    Putkonen M; Rauhala A; Pelliniemi TT; Remes K
    Ann Hematol; 2009 Jul; 88(7):673-80. PubMed ID: 19139894
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy of single-dose pegfilgrastim after chemotherapy for the mobilization of autologous peripheral blood stem cells in patients with malignant lymphoma or multiple myeloma.
    Kroschinsky F; Hölig K; Platzbecker U; Poppe-Thiede K; Ordemann R; Blechschmidt M; Oelschlaegel U; Schaich M; Hänel M; Bornhäuser M; Ehninger G
    Transfusion; 2006 Aug; 46(8):1417-23. PubMed ID: 16934080
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Allogeneic stem cell transplantation with peripheral blood stem cells mobilized by pegylated G-CSF.
    Hill GR; Morris ES; Fuery M; Hutchins C; Butler J; Grigg A; Roberts A; Bradstock K; Szer J; Kennedy G; Morton J; Durrant S
    Biol Blood Marrow Transplant; 2006 Jun; 12(6):603-7. PubMed ID: 16737933
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pre-mobilization therapy blood CD34+ cell count predicts the likelihood of successful hematopoietic stem cell mobilization.
    Fu P; Bagai RK; Meyerson H; Kane D; Fox RM; Creger RJ; Cooper BW; Gerson SL; Laughlin MJ; Koc ON; Lazarus HM
    Bone Marrow Transplant; 2006 Aug; 38(3):189-96. PubMed ID: 16850032
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Mobilization of peripheral blood stem cells for autologous transplantation patients with hematological malignancies: Influence of disease, mobilization method, age and sex.
    Zhang C; Chen X; Zhang X; Gao L; Kong P; Wang Q; Peng X; Liu H
    Transfus Apher Sci; 2008 Aug; 39(1):21-8. PubMed ID: 18599353
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A novel anti-inflammatory function of human galectin-1: inhibition of hematopoietic progenitor cell mobilization.
    Kiss J; Kunstár A; Fajka-Boja R; Dudics V; Tóvári J; Légrádi A; Monostori E; Uher F
    Exp Hematol; 2007 Feb; 35(2):305-13. PubMed ID: 17258079
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.